Helix BioPharma (TSE:HBP) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helix BioPharma reported a net loss of $9.26 million for fiscal 2024, driven by its continued investment in the development of its LDOS47 platform for cancer therapies. The company is refocusing its resources on combination therapy for Non-Small Cell Lung Carcinoma and plans to close its Edmonton laboratory by the end of October 2024.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money